LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Arbutus Biopharma Corp

Closed

3.7 1.09

Overview

Share price change

24h

Current

Min

3.64

Max

3.7

Key metrics

By Trading Economics

Income

27M

2.5M

Sales

9M

11M

Profit margin

23.494

Employees

44

EBITDA

27M

2.6M

Market Stats

By TradingEconomics

Market Cap

31M

671M

Previous open

2.61

Previous close

3.7

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Arbutus Biopharma Corp Chart

Past performance is not a reliable indicator of future results.

Related News

29 Aug 2025, 18:43 UTC

Major Market Movers

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29 Aug 2025, 15:07 UTC

Acquisitions, Mergers, Takeovers

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

30 Aug 2025, 08:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

29 Aug 2025, 20:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

29 Aug 2025, 20:24 UTC

Earnings

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29 Aug 2025, 20:17 UTC

Earnings

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 Aug 2025, 19:18 UTC

Market Talk

Oil Futures End Week With Modest Gains -- Market Talk

29 Aug 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29 Aug 2025, 18:36 UTC

Earnings

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29 Aug 2025, 18:26 UTC

Earnings

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29 Aug 2025, 17:48 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29 Aug 2025, 17:10 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29 Aug 2025, 16:57 UTC

Earnings

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 Aug 2025, 16:30 UTC

Acquisitions, Mergers, Takeovers

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29 Aug 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29 Aug 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29 Aug 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29 Aug 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29 Aug 2025, 16:24 UTC

Acquisitions, Mergers, Takeovers

BBVA Adjusts Offer for Banco de Sabadell

29 Aug 2025, 16:23 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29 Aug 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 Aug 2025, 16:06 UTC

Market Talk

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29 Aug 2025, 15:12 UTC

Market Talk
Earnings

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29 Aug 2025, 15:09 UTC

Earnings

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29 Aug 2025, 15:01 UTC

Market Talk

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29 Aug 2025, 14:49 UTC

Earnings

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 Aug 2025, 14:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 Aug 2025, 14:49 UTC

Market Talk

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29 Aug 2025, 14:48 UTC

Earnings

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29 Aug 2025, 14:43 UTC

Market Talk

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.